Severe covid-19 pneumonia: pathogenesis and clinical management
AH Attaway, RG Scheraga, A Bhimraj, M Biehl… - bmj, 2021 - bmj.com
Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
communities. Older age, male sex, and comorbidities increase the risk for severe disease …
Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Convalescent plasma antibody levels and the risk of death from Covid-19
Background Convalescent plasma has been widely used to treat coronavirus disease 2019
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
(Covid-19) under the presumption that such plasma contains potentially therapeutic …
Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
Accurate serological assays to detect antibodies to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
Convalescent plasma anti–SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization
E Salazar, SV Kuchipudi… - The Journal of …, 2020 - Am Soc Clin Investig
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
highlights the urgent need for assays that detect protective levels of neutralizing antibodies …
highlights the urgent need for assays that detect protective levels of neutralizing antibodies …
Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2
SN Neerukonda, R Vassell, R Herrup, S Liu, T Wang… - PloS one, 2021 - journals.plos.org
Pseudoviruses are useful surrogates for highly pathogenic viruses because of their safety,
genetic stability, and scalability for screening assays. Many different pseudovirus platforms …
genetic stability, and scalability for screening assays. Many different pseudovirus platforms …
[HTML][HTML] Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing …
E Salazar, PA Christensen, EA Graviss… - The American journal of …, 2021 - Elsevier
Coronavirus disease 2019 (COVID-19) convalescent plasma has emerged as a promising
therapy and has been granted Emergency Use Authorization by the US Food and Drug …
therapy and has been granted Emergency Use Authorization by the US Food and Drug …
Phenotype, susceptibility, autoimmunity, and immunotherapy between Kawasaki disease and coronavirus disease-19 associated multisystem inflammatory syndrome …
Coronavirus disease-19 (COVID-19) in children is usually mild but some are susceptible to a
Kawasaki disease (KD)-like multisystem inflammatory syndrome in children (MIS-C) in the …
Kawasaki disease (KD)-like multisystem inflammatory syndrome in children (MIS-C) in the …
The principles of antibody therapy for infectious diseases with relevance for COVID-19
A Casadevall, L Pirofski, MJ Joyner - MBio, 2021 - Am Soc Microbiol
Antibody therapies such as convalescent plasma and monoclonal antibodies have emerged
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …
as major potential therapeutics for coronavirus disease 2019 (COVID-19). Immunoglobulins …